[{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Dermatology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital T\u00fcbingen \/ Royal DSM"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Royal DSM"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Royal DSM"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Royal DSM | Diabetes Fonds","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Royal DSM | Diabetes Fonds","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Royal DSM | Diabetes Fonds"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Netherlands Asthma Foundation | Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Netherlands Asthma Foundation | Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Netherlands Asthma Foundation | Royal DSM"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Diabetes Fonds | Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Diabetes Fonds | Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Diabetes Fonds | Royal DSM"},{"orgOrder":0,"company":"Zaparackas and Knepper LTD","sponsor":"Northwestern University Feinberg School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase II","graph3":"Zaparackas and Knepper LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zaparackas and Knepper LTD \/ Northwestern University Feinberg School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Zaparackas and Knepper LTD \/ Northwestern University Feinberg School of Medicine"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Evolva SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northumbria University \/ Evolva SA","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Evolva SA"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Evolva SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Evolva SA","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Evolva SA"},{"orgOrder":0,"company":"Max Planck Institute for Human Cognitive and Brain Sciences","sponsor":"University of Leipzig | Evolva SA","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Max Planck Institute for Human Cognitive and Brain Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Planck Institute for Human Cognitive and Brain Sciences \/ University of Leipzig | Evolva SA","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck Institute for Human Cognitive and Brain Sciences \/ University of Leipzig | Evolva SA"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Gateway Health Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, Davis \/ Gateway Health Alliance","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Davis \/ Gateway Health Alliance"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Manitoba Institute of Child Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Manitoba \/ Manitoba Institute of Child Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Manitoba Institute of Child Health"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Royal DSM","highestDevelopmentStatusID":"9","companyTruncated":"University of Manitoba \/ Royal DSM"},{"orgOrder":0,"company":"Laval University","sponsor":"Atrium Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Atrium Innovations","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Atrium Innovations"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"1","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"Yardley Dermatology Associates","sponsor":"Topix Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Yardley Dermatology Associates","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yardley Dermatology Associates \/ Topix Pharmaceuticals, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Yardley Dermatology Associates \/ Topix Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Nutraceutical Discoveries, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University \/ Nutraceutical Discoveries, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Vanderbilt University \/ Nutraceutical Discoveries, Inc."},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Zina Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Partnership","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Zina Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Zina Biopharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Jupiter Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Catalent Pharma Solutions \/ Jupiter Neurosciences","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Jupiter Neurosciences"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Resveratrol","moa":"||NLRP3\/SIRT1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jupiter Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jupiter Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"MaineHealth","sponsor":"American Heart Association","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MaineHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaineHealth \/ American Heart Association","highestDevelopmentStatusID":"1","companyTruncated":"MaineHealth \/ American Heart Association"}]
Find Clinical Drug Pipeline Developments & Deals for PREVENTION 8 (RESVERATROL)
Details :
Nugevia MND, a scientifically formulated supplement, containing reservaterol & curcumin, designed to protect and enhance cognitive function and support overall brain health.
Details :
Under the agreement, Catalent Pharma will be responsible for the production of Jotrol (resveratrol) softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease.
Details :
The partnership aims to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease evaluating JOTROL, Jupiter’s patented resveratrol-based therapeutic platform.
Details :
The Company intends to use the proceeds to fund the Phase 2 trial of its product candidate Jotrol, an enhanced orally administered resveratrol formulation, in patients with Parkinson’s Disease
Details :
The Company intends to use the proceeds to fund the Phase 2 trial of its product candidate Jotrol, an enhanced orally administered resveratrol formulation, in patients with Parkinson’s Disease
Details :
Resveratrol is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Details :
Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.
Details :
Resveratrol is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.
Details :
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Reset All
